Sarepta Therapeutics IncFind Ratings Reports
SAREPTA THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. Sales have remained unchanged, but net income increased. SAREPTA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 2.61 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 30.78% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY16||Q1 FY15|
|Net Sales ($mil)||0.0||0.0|
|Net Income ($mil)||-59.77||-61.56|
|Balance Sheet||Q1 FY16||Q1 FY15|
|Cash & Equiv. ($mil)||139.85||166.22|
|Total Assets ($mil)||213.36||242.71|
|Total Debt ($mil)||20.98||6.38|
|Profitability||Q1 FY16||Q1 FY15|
|Gross Profit Margin||0.0||0.0|
|Return on Assets||-102.28||-69.66|
|Return on Equity||-157.05||-84.21|
|Debt||Q1 FY16||Q1 FY15|
|Share Data||Q1 FY16||Q1 FY15|
|Shares outstanding (mil)||45.77||41.35|
|Div / share||0.0||0.0|
|Book value / share||3.04||4.85|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||7594884.0||2202842.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 6.73 indicates a significant premium versus the S&P 500 average of 2.80 and a significant discount versus the industry average of 10.73. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. The valuation analysis reveals that, SAREPTA THERAPEUTICS INC seems to be trading at a premium to investment alternatives within the industry.
|SRPT NM||Peers 38.57||SRPT NM||Peers 20.77|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SRPT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SRPT's P/CF is negative making the measure meaningless.
|SRPT NM||Peers 111.79||SRPT NA||Peers 1.06|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SRPT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SRPT 6.73||Peers 10.73||SRPT -21.30||Peers -16.43|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SRPT is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, SRPT is expected to significantly trail its peers on the basis of its earnings growth rate.
|SRPT 748.38||Peers 370.84||SRPT -65.85||Peers 40.78|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SRPT is trading at a significant premium to its industry.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
SRPT significantly trails its peers on the basis of sales growth